Nature Search

Natural history of SPP1 signaling in NF1 tumors

Kimani Njoya
Huda Zayed
Daochun Sun
ResearchOpen Access06 Oct 2025
npj Precision Oncology

Volume: 9, P: 1-9
Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring

Yu Shi
Weina Gao
Tony Hunter
Amendments and Corrections30 Nov 2021
Nature

Volume: 600, P: E18
Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma

Clinical management of pancreatic cancer remains challenging. Here, the authors suggest SMARCD3 as a potential epigenetic dependency establishing the metabolic landscape in aggressive pancreatic cancer cells and as a potential therapeutic target in pancreatic cancer.

L. Paige Ferguson
Jovylyn Gatchalian
Tannishtha Reya
ResearchOpen Access18 Jan 2023
Nature Communications

Volume: 14, P: 1-17
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring

A systematic proteomic investigation of disease mediators secreted by pancreatic stellate cells identifies leukaemia inhibitory factor (LIF) as a key factor that acts on cancer cells, promoting tumour progression and chemoresistance.

Yu Shi
Weina Gao
Tony Hunter
Research17 Apr 2019
Nature

Volume: 569, P: 131-135
A stem cell reporter based platform to identify and target drug resistant stem cells in myeloid leukemia

Identifying leukaemia stem cells (LSC) and defining how they drive tumourigenesis might aid in the treatment of disease. Here, the authors show that a reporter Musashi 2 can serve as a platform to effectively identify leukemic stem cells and it is used to define Syndecan-1 as a dependency for these aggressive, therapy resistant cells.

Kyle Spinler
Jeevisha Bajaj
Tannishtha Reya
ResearchOpen Access26 Nov 2020
Nature Communications

Volume: 11, P: 1-15
Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma

The stem cell determinant Musashi (Msi) is a key mediator of pancreatic cancer progression and therapy resistance.

Raymond G. Fox
Nikki K. Lytle
Tannishtha Reya
Research06 Jun 2016
Nature

Volume: 534, P: 407-411
Stem cell fate in cancer growth, progression and therapy resistance

This Review discusses how cells with stem cell characteristics often serve as the tumour cell of origin, as they are preferentially primed for transformation. Furthermore, the activation of stem cell programmes can be crucial for promoting cancer progression and therapy resistance.

Nikki K. Lytle
Alison G. Barber
Tannishtha Reya
Reviews18 Sept 2018
Nature Reviews Cancer

Volume: 18, P: 669-680

Search

Filter By:

Natural history of SPP1 signaling in NF1 tumors

Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring

Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring

A stem cell reporter based platform to identify and target drug resistant stem cells in myeloid leukemia

Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma

Stem cell fate in cancer growth, progression and therapy resistance

Search

Quick links